EMA ups Fabrazyme demand despite short supply

The shortage of Genzyme's Fabry disease treatment Fabrazyme is driving regulatory action in Europe. The European Medicines Agency now recommends that doctors return to prescribing the full dosage.

It had previously recommended use of a lower dose to help stretch supplies, which had dwindled due to Genzyme's shutting of a Boston-area plant following a viral contamination. But the regulator is now seeing an increase in adverse events that corresponds with the number of patients on the lower dose.

The full-dose recommendation is a problem for Genzyme, which is fighting its way back from the plant shutdown under a consent decree with the FDA. It's now at about 60 percent of production capacity, according to the company. The recommendation may drive patients to competing drug Replagal from Shire.

For its part, the regulator "remains concerned about the continued supply shortages," according to a statement. It is "monitoring the implementation of their improvement measures."  

- here's the EMA statement

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.